Effect of Toscilizumab and Infliximab on Covid 19
Phase 2
Recruiting
- Conditions
- covid19.covid19
- Registration Number
- IRCT20220208053970N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
People with Covid 19 (based on RT-PCR test for SARS-CoV-19 virus or CT scan criteria)
People between the ages of 25 and 70
Symptoms indicate severe disease (more than 50% of lung involvement in CT or oxygen saturation below 90% or respiratory rate greater than 30 per minute)
Elevated CRP, ferritin and other inflammatory markers
Exclusion Criteria
People who test positive for PPD, HCV, HBV and have infections other than Covid 19 infection
Pregnancy and pregnancy intention
Mild involvement or in the early stages of Covid 19
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ferritin. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Elisa.;D-dimer. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;C-Reactive Protein. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;Lactate Dehydrogenase. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;Complete blood count. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: sysmex.;Erythrocyte Sedimentation Rate. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Sediman Reader.
- Secondary Outcome Measures
Name Time Method